# PREPARATION OF BACTERIAL POLYSACCHARIDE IMMUNE GLOBULIN

> **NIH NIH R01** · DANA-FARBER CANCER INST · 1989 · $17,973

## Abstract

The prevention of H. influenzae type b, (Hib), pneumococcal and
meningococcal infections would be a major advance.  These organisms are the
major bacterial causes of meningitis, blood stream infection, pneumonia and
middle ear infections in children and adults.  The work accomplished during
the first two years of this grant has demonstrated the feasibility of
preparing a human hyperimmune globulin (termed Bacterial Polysaccharide
Immune Gobulin okr BPIG) high concentrations of antibody against these
organisms.  The pharmacologic studies indicate that "protective" antibody
levels to Hib are maintained for at least 4 months after a single im
dose.   Passive BPIG prophylaxis therefore has a high probability of
success.  Even if capsular polysaaccharide vaccines of improved
immunogenicity can be developed, passive prophylaxis used instead of or in
conjuction with active immunization is likely to be useful in selected
high-risk children.

We propose to continue our investigations by preparing sufficient BPIG for
additional pharmaclogic studies and large-scale efficacy trials in the
prevention of bacteremia meningitis, pneumonia, and recurrent otitis
media.  In addition, we will optimize methods of production by immunizing
donors with new maximally immunogenic vaccines and evaluate genetic markers
which identify donors with high and persistent IgG-class antibody
responses.  We will develop guidelines for standardizing the specific
antibody concentrations required in the final globulin.  An intravenous
formulation of BPIG will be evaluated in humans.  Experimental studies will
be done to evaluate the safety and efficacy of hyperimmune globulin in the
treatment of establishd Hib infections.

Finally, we will exploit the availability of large volumes of human
hyperimmune plasma by purifying IgG, IgM and IgA immunoglobulins and
examining their actions and interactions against Hib in bactericidal and
opsonophagocytic assays and in animal models.

## Key facts

- **NIH application ID:** 3127705
- **Project number:** 3R01AI018125-08S1
- **Recipient organization:** DANA-FARBER CANCER INST
- **SAM.gov UEI:** DPMGH9MG1X67
- **Principal Investigator:** George R Siber
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $17,973
- **Award type:** 3
- **Project period:** 1981-08-01 → 1989-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3127705

## Citation

> US National Institutes of Health, RePORTER application 3127705, PREPARATION OF BACTERIAL POLYSACCHARIDE IMMUNE GLOBULIN (3R01AI018125-08S1). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3127705. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*